Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
D Gale, K Heider, A Ruiz-Valdepenas, S Hackinger, M Perry, G Marsico, V Rundell, J Wulff, G Sharma, H Knock, J Castedo, W Cooper, H Zhao, C G Smith, S Garg, S Anand, K Howarth, D Gilligan, S V Harden, D M Rassl, R C Rintoul, N Rosenfeld, D Gale, K Heider, A Ruiz-Valdepenas, S Hackinger, M Perry, G Marsico, V Rundell, J Wulff, G Sharma, H Knock, J Castedo, W Cooper, H Zhao, C G Smith, S Garg, S Anand, K Howarth, D Gilligan, S V Harden, D M Rassl, R C Rintoul, N Rosenfeld
Abstract
Background: Identification of residual disease in patients with localized non-small cell lung cancer (NSCLC) following treatment with curative intent holds promise to identify patients at risk of relapse. New methods can detect circulating tumour DNA (ctDNA) in plasma to fractional concentrations as low as a few parts per million, and clinical evidence is required to inform their use.
Patients and methods: We analyzed 363 serial plasma samples from 88 patients with early-stage NSCLC (48.9%/28.4%/22.7% at stage I/II/III), predominantly adenocarcinomas (62.5%), treated with curative intent by surgery (n = 61), surgery and adjuvant chemotherapy/radiotherapy (n = 8), or chemoradiotherapy (n = 19). Tumour exome sequencing identified somatic mutations and plasma was analyzed using patient-specific RaDaR™ assays with up to 48 amplicons targeting tumour-specific variants unique to each patient.
Results: ctDNA was detected before treatment in 24%, 77% and 87% of patients with stage I, II and III disease, respectively, and in 26% of all longitudinal samples. The median tumour fraction detected was 0.042%, with 63% of samples <0.1% and 36% of samples <0.01%. ctDNA detection had clinical specificity >98.5% and preceded clinical detection of recurrence of the primary tumour by a median of 212.5 days. ctDNA was detected after treatment in 18/28 (64.3%) of patients who had clinical recurrence of their primary tumour. Detection within the landmark timepoint 2 weeks to 4 months after treatment end occurred in 17% of patients, and was associated with shorter recurrence-free survival [hazard ratio (HR): 14.8, P <0.00001] and overall survival (HR: 5.48, P <0.0003). ctDNA was detected 1-3 days after surgery in 25% of patients yet was not associated with disease recurrence. Detection before treatment was associated with shorter overall survival and recurrence-free survival (HR: 2.97 and 3.14, P values 0.01 and 0.003, respectively).
Conclusions: ctDNA detection after initial treatment of patients with early-stage NSCLC using sensitive patient-specific assays has potential to identify patients who may benefit from further therapeutic intervention.
Keywords: cell-free DNA (cfDNA); circulating tumour DNA (ctDNA); early detection; liquid biopsy; minimal residual disease (MRD); non-small cell lung cancer (NSCLC).
Conflict of interest statement
Disclosure NR and DGa are co-founders, and NR, DGa, MP, KHo, SH, GM, CGS and GS are current or former employees/officers/consultants of Inivata Ltd. Inivata provided analysis of samples using the RaDaR™ assays. DGa and KHe are current employees of AstraZeneca Inc. All other authors have declared no conflicts of interest.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures
References
- Globocan 2020. World Health Organisation, International Agency for Research on Cancer. Available at. Accessed March 18, 2020.
- Cancer Research UK. 2020. Available at. Accessed March 18, 2020.
- NICE. Lung cancer in adults: treatments with curative intent. Webpage. 2021. Available at. Accessed March 18, 2020.
- Wan J.C.M., Massie C., Garcia-Corbacho J., et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–238.
- Dawson S.-J., Tsui D.W.Y., Murtaza M., et al. Analysis of circulating tumour DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–1209.
- Parkinson C.A., Gale D., Piskorz A.M., et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13(12)
- Vogelstein B., Kinzler K.W. Digital PCR. Proc Natl Acad Sci U S A. 1999;96(16):9236–9241.
- Diehl F., Schmidt K., Choti M.A., et al. Circulating mutant DNA to assess tumour dynamics. Nat Med. 2008;14(9):985–990.
- Forshew T., Murtaza M., Parkinson C., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68.
- Murtaza M., Dawson S.-J., Tsui D.W.Y., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108–112.
- Murtaza M., Dawson S.-J., Pogrebniak K., et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 2015;6:8760.
- Kinde I., Wu J., Papadopoulos N., Kinzler K.W., Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(23) :9530-9335.
- Newman A.M., Lovejoy A.F., Klass D.M., et al. Integrated digital error suppression for improved detection of circulating tumour DNA. Nat Biotechnol. 2016;34(5):547–555.
- Wan J.C.M., Heider K., Gale D., et al. ctDNA monitoring using patient-specific sequencing and integration of variant reads. Sci Transl Med. 2020;12(548)
- Mcdonald B.R., Contente-cuomo T., Sammut S.-J., et al. Personalized circulating tumour DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Transl Med. 2019;11(504)
- Parsons H.A., Rhoades J., Reed S.C., et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin Cancer Res. 2020;26(11):2556–2564.
- Kurtz D.M., Soo J., Co Ting Keh L., et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumour DNA. Nat Biotechnol. 2021;39(12):1537–1547.
- Marsico G., Sharma G., Perry M., et al. Abstract 3097: Analytical development of the RaDaR™ assay, a highly sensitive and specific assay for the monitoring of minimal residual disease. Cancer Res. 2020;80(suppl 16):3097.
- Garcia-Murillas I., Schiavon G., Weigelt B., et al. Mutation tracking in circulating tumour DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133.
- Tie J., Wang Y., Tomasetti C., et al. Circulating tumour DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346) 346ra92-346ra92.
- Chaudhuri A.A., Chabon J.J., Lovejoy A.F., et al. Early detection of molecular residual disease in localized lung cancer by circulating tumour DNA profiling. Cancer Discov. 2017;7(12):1394–1403.
- Azad T.D., Chaudhuri A.A., Fang P., et al. Circulating tumour DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology. 2020;158(3):494–505.e6.
- Moding E.J., Nabet B.Y., Alizadeh A.A., Diehn M. Detecting liquid remnants of solid tumours: circulating tumour DNA minimal residual disease. Cancer Discov. 2021;11(12):2968–2986.
- Chen K., Zhao H., Shi Y., et al. Perioperative dynamic changes in circulating tumour DNA in patients with lung cancer (DYNAMIC) Clin Cancer Res. 2019;25(23):7058–7067.
- Zviran A., Schulman R.C., Shah M., et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26(7):1114–1124.
- Wan J.C.M., Mughal T.I., Razavi P., et al. Liquid biopsies for residual disease and recurrence. Med. 2021;2(12):1292–1313.
- Moding E.J., Liu Y., Nabet B.Y., et al. Circulating tumour DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nat Cancer. 2020;1(2):176–183.
- Powles T., Assaf Z.J., Davarpanah N., et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595:432–437.
- Rostami A., Bratman S.V. Utilizing circulating tumour DNA in radiation oncology. Radiother Oncol. 2017;124(3):357–364.
- Heider K, Wan JCM, Gale D, et al. ctDNA detection by personalised assays in early-stage NSCLC. MedRxiv. 2021. 10.1101/2021.06.01.21258171. Available at . Accessed March 18, 2022.
- Cibulskis K., Lawrence M.S., Carter S.L., et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–219.
- Broad Institute. Mutect2 [Internet]. GATK. Available at. Accessed March 18, 2022.
- Lai Z., Markovets A., Ahdesmaki M., et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44(11) :e108-e108.
- Garrison E., Marth G. Haplotype-based variant detection from short-read sequencing [Internet]. 2012 . Available at. Accessed March 18, 2022.
- Gale D., Lawson A.R.J., Howarth K., et al. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS One. 2018;13(3)
- Plagnol V., Woodhouse S., Howarth K., et al. Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling. PLoS One. 2018;13(3)
- Abbosh C., Swanton C., Birkbak N.J. Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses. Ann Oncol. 2019;30(3):358–359.
- Li H. 2013. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM; p. 1303. :arXiv. Available at. Accessed March 18, 2022.
- Abbosh C., Birkbak N.J., Wilson G.A., et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451.
- Abbosh C., Frankell A., Garnett A., et al. Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: a lung TRACERx study. AACR. Cancer Res. 2020;80(suppl 16) Abstract CT023.
Source: PubMed